The Drugs for Neglected Diseases Initiative (DNDi) is testing new treatments against sleeping sickness, leishmaniasis, Chagas disease and AIDS

For those in the field it goes by the name of the 10/90 gap: the fact that only 10 per cent of global health research is devoted to conditions that account for 90 per cent of the global disease burden. It was to challenge this imbalance that the Drugs for Neglected Diseases Initiative (DNDi) came into being in 2003. Coinciding with its tenth anniversary year, the organization has been granted the BBVA Foundation Frontiers of Knowledge Award in the Development Cooperation category. Its Executive Director, Bernard Pécoul, announced this morning at a press conference that new drugs the DNDi is working on “could drastically change the management of some of these diseases.”